ClinicalTrials.gg
CompletedNCT01397448Updated Nov 26, 2014Results posted

Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)

A Phase 2/3 interventional study of E3810 and E3810 in Gastric or Duodenal Ulcers Caused by Low-dose Aspirin, sponsored by Eisai Co., Ltd.. Completed at 49 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-11-26.

Sponsored by Eisai Co., Ltd. · Phase 2/3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
472
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 29 studies in Stomach Ulcer with a site in Japan — none open to participants now, none under way, none of them phase 3. Stomach Ulcer · Japan.

Enrollment
5th of 20
472 · median 400
Started
2011
with 7 others
Phase 2/3
3 of 29
none open now
Registered
12th of 29
by date
Lead sponsor
4 of 29
Eisai Co., Ltd.

Among the 29 studies in Stomach Ulcer with a site in Japan, this one is the 5th largest by enrollment of the 20 interventional ones that give a count, is one of 8 that started in 2011, is one of 3 in phase 2/3, and was the 12th registered.

Stomach Ulcer

116 studies on the registry are indexed under Stomach Ulcer; 13 are open to participants now.

Browse Stomach Ulcer studies →

Open to participants now

None of the 29 studies in Stomach Ulcer with a site in Japan is open now. The open studies under Stomach Ulcer, anywhere →

Who these studies take

Of the 10 Stomach Ulcer studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies in Stomach Ulcer with a site in Japan as a file.
02

Study summary

The primary objective of this study to evaluate the effect of preventing recurrence of gastric or duodenal ulcers by administering E3810 5 mg or 10 mg tablets once daily or Teprenone 150 mg/day (50 mg three times daily) as a control to patients receiving low-dose aspirin and thereby examine the superiority of E3810 over Teprenone.

03

Conditions studied

  • Gastric or Duodenal Ulcers Caused by Low-dose Aspirin

Keywords

  • Rabeprazole
  • proton pump inhibitor
  • Acetylsalicylic Acid
  • Aspirin
  • Gastric Ulcer
  • Duodenal Ulcer
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Require long-term administration of low-dose aspirin (81 mg/day or 100 mg/day)
  • Confirmed to have a history of gastric or duodenal ulcer

Exclusion criteria

Exclusion Criteria

-Confirmed to have acute gastro duodenal mucosal lesions, gastric or duodenal ulcer, or upper gastrointestinal (esophagus, stomach, duodenum) bleeding Confirmed to have reflux esophagitis or long segment Barrett's esophagus

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
472 participants (actual)

Study arms

  • Experimental
    E3810 5 mg

    Drug: E3810

  • Experimental
    E3810 10 mg

    Drug: E3810

  • Active comparator
    Teprenone 150 mg

    Drug: Teprenone

Interventions

  • DrugE3810

    Drug pages: Rabeprazole · E-3810

    E3810 5 mg/day Group: Orally administered E3810 5 mg tablets and E3810 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.

  • DrugE3810

    Drug pages: Rabeprazole · E-3810

    E3810 10 mg Group: Orally administered E3810 5 mg placebo tablets and 10 mg tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.

  • Teprenone 150 mg/day Group: Orally administered E3810 5 mg placebo tablets and 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg capsules three times daily after each meal.

06

What researchers measure

Primary outcomes

  1. Cumulative Recurrent Rates of Gastric or Duodenal Ulcers

    Mucosal injuries with a white coat measuring 3 mm in diameter will be diagnosed as ulcers. When ulcer is confirmed by endoscopic examination during the trial, it will be regarded as recurrence of ulcer and the trial will be discontinued for the patient involved.

    Time frame: 24 weeks

Secondary outcomes

  1. Cumulative Incidence of Bleeding Ulcers

    Time frame: 24 weeks

07

Results

Posted Oct 23, 2014

Participant flow

Participant flow — Overall Study
MilestoneRabeprazole 5 mgRabeprazole 10 mgTeprenone 150 mg
Started156157158
Completed138142140
Not completed181518
Withdrew: Adverse event446
Withdrew: Withdrawal by subject443
Withdrew: Lack of efficacy205
Withdrew: Other874

Outcome measures

SecondaryCumulative Incidence of Bleeding Ulcers
Time frame:
24 weeks
Reported as:
Number · Events/100 participants/24 weeks
Cumulative Incidence of Bleeding Ulcers
Events/100 participants/24 weeksRabeprazole 5 mgRabeprazole 10 mgTeprenone 150 mg
Cumulative Incidence of Bleeding Ulcers0 (0 to 0)0 (0 to 0)4.6 (2.24 to 9.48)
PrimaryCumulative Recurrent Rates of Gastric or Duodenal Ulcers

Mucosal injuries with a white coat measuring 3 mm in diameter will be diagnosed as ulcers. When ulcer is confirmed by endoscopic examination during the trial, it will be regarded as recurrence of ulcer and the trial will be discontinued for the patient involved.

Time frame:
24 weeks
Reported as:
Number · Events/100 participants/24 weeks
Cumulative Recurrent Rates of Gastric or Duodenal Ulcers
Events/100 participants/24 weeksRabeprazole 5 mgRabeprazole 10 mgTeprenone 150 mg
Cumulative Recurrent Rates of Gastric or Duodenal Ulcers2.8 (1.04 to 7.17)1.4 (0.35 to 5.51)21.7 (15.84 to 29.27)
Statistical analysis
  • Rabeprazole 5 mg vs Teprenone 150 mg · Log Rank · p = <0.001 · Hazard ratio (hr): 0.11 · 95% CI 0.04 to 0.31
  • Rabeprazole 10 mg vs Teprenone 150 mg · Log Rank · p = <0.001 · Hazard ratio (hr): 0.05 · 95% CI 0.01 to 0.23

Adverse events

Collected over 24 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rabeprazole 5 mg—10/156 (6.4%)48/156 (30.8%)
Rabeprazole 10 mg—6/157 (3.8%)46/157 (29.3%)
Teprenone 150 mg—10/158 (6.3%)41/158 (25.9%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventRabeprazole 5 mgRabeprazole 10 mgTeprenone 150 mg
Angina pectorisCardiac disorders1/1560/1572/158
Pancreatitis acuteGastrointestinal disorders1/1560/1570/158
VomitingGastrointestinal disorders1/1560/1570/158
Spinal compression fractureInjury, poisoning and procedural complications1/1560/1570/158
Diabetes mellitus inadequate controlMetabolism and nutrition disorders1/1560/1570/158
HypoglycaemiaMetabolism and nutrition disorders1/1560/1570/158
Rotator cuff syndromeMusculoskeletal and connective tissue disorders1/1560/1570/158
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1560/1570/158
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1560/1570/158
Gastric adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1560/1570/158
Most frequent other events
Most frequent other events
EventRabeprazole 5 mgRabeprazole 10 mgTeprenone 150 mg
NasopharyngitisInfections and infestations25/15622/15725/158
PharyngitisInfections and infestations6/1561/1572/158
DiarrhoeaGastrointestinal disorders4/1566/1572/158
EczemaSkin and subcutaneous tissue disorders1/1566/1571/158
ConstipationGastrointestinal disorders1/1565/1576/158
Upper respiratory tract infectionInfections and infestations5/1563/1572/158
HypertensionVascular disorders0/1565/1573/158
ContusionInjury, poisoning and procedural complications4/1560/1573/158
Diabetes mellitusMetabolism and nutrition disorders4/1562/1571/158
EpistaxisRespiratory, thoracic and mediastinal disorders0/1561/1574/158

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Rabeprazole 5 mgRabeprazole 10 mgTeprenone 150 mgTotal
Mean69.3 ± 8.970.1 ± 9.669.4 ± 7.969.6 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)Rabeprazole 5 mgRabeprazole 10 mgTeprenone 150 mgTotal
Female353641112
Male121121117359
Antiplatelet Drug or Anticoagulant Drug
Antiplatelet Drug or Anticoagulant Drug(Participants)Rabeprazole 5 mgRabeprazole 10 mgTeprenone 150 mgTotal
Yes30343599
No126123123372
Daily Dose of Low-Dose Aspirin
Daily Dose of Low-Dose Aspirin(Participants)Rabeprazole 5 mgRabeprazole 10 mgTeprenone 150 mgTotal
81 mg12141642
100 mg144143142429
Diagnostic Test of H.pylori. (IgG Antibody)
Diagnostic Test of H.pylori. (IgG Antibody)(Participants)Rabeprazole 5 mgRabeprazole 10 mgTeprenone 150 mgTotal
Positive726777216
Negative849081255
Primary Disease
Primary Disease(Participants)Rabeprazole 5 mgRabeprazole 10 mgTeprenone 150 mgTotal
Angina Pectoris (Yes)686366197
Angina Pectoris (No)889492274
Myocardial Infarction (Yes)27313391
Myocardial Infarction (No)129126125380
Ischemic Cerebrovascular Disease (Yes)797778234
Ischemic Cerebrovascular Disease (No)778080237
Coronary Arterial Bypass Grafting or PTCA (Yes)525148151
Coronary Arterial Bypass Grafting or PTCA (No)104106110320
Other (Yes)610925
Other (No)150147149446
08

Study locations

49 sites
  • Kasugai, Aichi, Japan
  • Nagoya, Aichi, Japan
  • Ichikawa, Chiba, Japan
  • Chikushino, Fukuoka, Japan
  • Kitakyushu, Fukuoka, Japan
  • Onga, Fukuoka, Japan
  • Maebashi, Gunma, Japan
  • Asahikawa, Hokkaido, Japan
  • Sapporo, Hokkaido, Japan
  • Tomakomai, Hokkaido, Japan
  • Itami, Hyogo, Japan
  • Kobe, Hyogo, Japan
  • Hitachi, Ibaraki, Japan
  • Fujisawa, Kanagawa, Japan
  • Kawasaki, Kanagawa, Japan
  • Sagamihara, Kanagawa, Japan
  • Yokohama, Kanagawa, Japan
  • Hitoyoshi, Kumamoto, Japan
  • Ebino, Miyazaki, Japan
  • Chikuma, Nagano, Japan
  • Matsumoto, Nagano, Japan
  • Suzaka, Nagano, Japan
  • Beppu, Oita, Japan
  • Yufu, Oita, Japan
  • Daito, Osaka, Japan
  • Hirakata, Osaka, Japan
  • Matsubara, Osaka, Japan
  • Takatsuki, Osaka, Japan
  • Yao, Osaka, Japan
  • Karatsu, Saga, Japan
  • Ureshino, Saga, Japan
  • Izumo, Shimane, Japan
  • Hamamatsu, Shizuoka, Japan
  • Ohtawara, Tochigi, Japan
  • Mitaka, Tokyo, Japan
  • Setagaya, Tokyo, Japan
  • Shinjuku, Tokyo, Japan
  • Fukuoka, Japan
  • Gifu, Japan
  • Kochi, Japan
  • Kumamoto, Japan
  • Kyoto, Japan
  • Miyazaki, Japan
  • Nagano, Japan
  • Nagasaki, Japan
  • Oita, Japan
  • Osaka, Japan
  • Saga, Japan
  • Shizuoka, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Mar 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2011
First posted
Jul 19, 2011
Start
Jul 2011
Primary completionActual
Mar 2013
CompletionActual
Jun 2013
Results first posted
Oct 23, 2014
Last update
Nov 26, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01397448
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Jul 19, 2011
Start date
Jul 2011
Primary completion
Mar 2013
Completion
Jun 2013
Results posted
Oct 23, 2014
Last update
Nov 26, 2014

Study contacts

Nobuyuki Sugisaki
study director · Japan/Asia Clinical Research Product Creation Unit
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rabeprazole · E-3810

Start the discussion